In a mouse model of lymphoma, high TOP2a expression is an indicator of doxorubicin efficacy, while low TOP1 expression is associated with resistance to the topoisomerase I inhibitor camptothecin and increased responsiveness to doxorubicin 42. The gene discussed is TOP1; the disease is lymphoma.